✦ LIBER ✦

Results of a phase II, multiple-dose, randomized trial of an anti-CD23 monoclonal antibody (IDEC-152) in patients with seasonal allergic rhinitis

✍ Scribed by Casale, T.B.; Busse, W.W.; Lizambri, R.G.; Korenblat, P.E.; Schoenwetter, W.F.; Weiler, J.M.; Rosenwasser, L.J.; Nayak, A.S.; Perea, R.M.; Totoritis, M.C.

Book ID: 119491248
Publisher: Elsevier Science
Year: 2003
Tongue: English
Weight: 140 KB
Volume: 111
Category: Article
ISSN: 1097-6825
DOI: 10.1016/s0091-6749(03)80182-3

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Allergic asthma and an anti-CD23 mAb (ID

Allergic asthma and an anti-CD23 mAb (IDEC-152) Results of a phase I, single-dose, dose-escalating clinical trial

✍ Rosenwasser, L 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 365 KB

Ocrelizumab, a humanized anti-CD20 monoc

Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I/II randomized, blinded, placebo-controlled, dose-ranging study

✍ Mark C. Genovese; Jeffrey L. Kaine; Mitchell B. Lowenstein; José Del Giudice; An 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 623 KB

Atacicept in patients with rheumatoid ar

Atacicept in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor antagonist therapy: Results of a phase II, randomized, placebo-controlled, dose-finding trial

✍ M. C. Genovese; N. Kinnman; G. de La Bourdonnaye; C. Pena Rossi; P. P. Tak 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 242 KB 👁 2 views

493 Safety Profile and Signal of Efficac

493 Safety Profile and Signal of Efficacy of a Non-Fcr-Binding, Fully Human Anti-Cd3 Monoclonal Antibody in Patients with Moderate to Severe Crohn's Disease- Results of a Phase I/Iia, Double Blind, Placebo-Controlled, Randomized, Dose Escalation Study

✍ Christien J. van der Woude; Pieter C. Stokkers; Ad A. van Bodegraven; Gert A. Va 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 87 KB

A phase II, randomized, double-blind, pl

A phase II, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of MDX-1100, a fully human anti-CXCL10 monoclonal antibody, in combination with methotrexate in patients with rheumatoid arthritis

✍ Michael Yellin; Igor Paliienko; Andra Balanescu; Semen Ter-Vartanian; Vira Tselu 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 199 KB

505 POSTER Preliminary results of a phas

505 POSTER Preliminary results of a phase II clinical trial of the anti EGFR monoclonal antibody Nimotuzumab in combination with whole brain radiation therapy in patients diagnosed with advanced non-small cell lung cancer tumors unresectable brain metastases

✍ A. Macias; E. Neninger; E. Santiesteban; J. Figueredo; A. Hernandez; F. Aguirre; 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 72 KB